Pharmacies across the nation are bracing for a significant increase in demand for weight-loss medications. Three-quarters of community pharmacies expect heightened patient interest in the coming months. This surge follows the introduction of new prescription-only options, including GLP-1 receptor agonists like oral semaglutide, which launched in the UK this year. The Royal College of Pharmacy has highlighted concerns about supply chain pressures. Pharmacies may face challenges meeting sudden spikes in requests for these high-cost treatments.
At the same time, the National Institute for Health and Care Excellence (NICE) issued its first UK guidance for PMOS treatment in July 2026. The guidance provides clinical recommendations for a condition previously without standardized protocols.
Research presented in the same period found that blood pressure and cholesterol levels in older adults with obesity are comparable to those with healthy body mass indexes. This challenges assumptions about cardiovascular risk in this population. The study adds to ongoing discussions about how obesity is assessed and managed in elderly patients.
Regulatory action also intensified, with the General Pharmaceutical Council (GPhC) taking measures against misleading advertising by retailers, including Tesco, regarding weight-loss products. The regulator emphasized the importance of accurate information to prevent false expectations or unsafe self-medication practices.
NHS England is developing a new framework to deploy pharmacists during mass casualty incidents, expanding their role beyond traditional community settings. The initiative seeks to leverage pharmacists’ expertise in medication management during emergency response scenarios.
Amid these developments, the Royal College of Pharmacy warned against proposals to shorten training time for internationally qualified pharmacists. The college argues that changes could compromise patient safety standards. The college emphasized maintaining rigorous equivalency assessments to ensure all practitioners meet UK competency requirements.
The convergence of new treatment options, evolving clinical guidelines, and regulatory adjustments reflects a period of rapid change in pharmacy practice. While demand for weight-loss medications signals growing public interest in accessible treatments, the sector faces multiple pressures. These include supply constraints and evolving roles that will require coordinated responses from providers, regulators, and policymakers alike.